Trial · NCT01293539

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

NCT01293539, Phase 2, Terminated, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; results first posted 2017-07-21

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma. Trials, record NCT01293539. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01293539

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma
NCT number: NCT01293539
Status: Terminated
Phases: Phase 2
Enrollment: 10 participants, actual
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions: Retinoblastoma
Interventions: Melphalan hydrochloride
First posted: 2011-02-10
Last updated: 2018-11-27
Results first posted: 2017-07-21

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients Who Complete Therapy Without the Need for Additional Treatment Including Systemic Chemotherapy, External Beam Radiation, or Enucleation.	Within the first six months after the initial treatment.	The primary objective of this study is to show that intra-arterial delivery of the chemotherapeutic agent is successful in treating intraocular retinoblastoma, defined as avoiding systemic chemotherapy, external beam radiation, and enucleation.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Patients Who Complete Therapy Without the Need for Additional Treatment Including Systemic Chemotherapy, External Beam Radiation, or Enucleation.	Within the first six months after the initial treatment.		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Patients Who Complete Therapy Without the Need for Additional Treatment Including Systemic Chemotherapy, External Beam Radiation, or Enucleation.	Intra-arterial Chemotherapy		10		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Intra-arterial Chemotherapy	10
Overall Study	COMPLETED	Intra-arterial Chemotherapy	9
Overall Study	NOT COMPLETED	Intra-arterial Chemotherapy	1

Source ClinicalTrials.gov

Adverse events17

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Eyelid edema & erythema	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Eyelid function disorder	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Injury - cut to lip during play	Injury, poisoning and procedural complications	Intra-arterial Chemotherapy	1	10	1
other	Eyelid function disorder	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Eye pain	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Mild swelling	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Cough	Respiratory, thoracic and mediastinal disorders	Intra-arterial Chemotherapy	2	10	2
other	Conjunctivitis	Eye disorders	Intra-arterial Chemotherapy	1	10	1
other	Flu-like symptoms	General disorders	Intra-arterial Chemotherapy	1	10	1
other	Cough	Respiratory, thoracic and mediastinal disorders	Intra-arterial Chemotherapy	2	10	2

1 to 10 of 17Source ClinicalTrials.gov

See all 17 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Intra-arterial Chemotherapy
Total, other adverse events	Intra-arterial Chemotherapy	6	10
Total, serious adverse events	Intra-arterial Chemotherapy	3	10

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18342944	BACKGROUND	PubMed
22084221	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01293539

GET https://conductscience.org/api/trials/v1/NCT01293539/registered

API reference For AI assistants